These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 28863952)
41. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085 [TBL] [Abstract][Full Text] [Related]
42. Partly solid pulmonary nodules: waiting for change or surgery outright? Seok Y; Cho S; Kim K; Jheon S Interact Cardiovasc Thorac Surg; 2014 Oct; 19(4):556-60. PubMed ID: 24981106 [TBL] [Abstract][Full Text] [Related]
43. Comparisons of clinical outcomes in patients with and without a preoperative tissue diagnosis in the persistent malignant-looking, ground-glass-opacity nodules. Choi SH; Chae EJ; Shin SY; Kim EY; Kim JE; Lee HJ; Oh SY; Lee SM Medicine (Baltimore); 2016 Aug; 95(34):e4359. PubMed ID: 27559945 [TBL] [Abstract][Full Text] [Related]
44. Pregnancy may have little influence on ground-glass opacities suspected for lung adenocarcinoma. Bai J; Deng C; Fu F; Li D; Ma Z; Ma X; Zhang Y; Chen H J Cancer Res Clin Oncol; 2023 Apr; 149(4):1383-1389. PubMed ID: 35445333 [TBL] [Abstract][Full Text] [Related]
48. Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. Brandt WS; Bouabdallah I; Tan KS; Park BJ; Adusumilli PS; Molena D; Bains MS; Huang J; Isbell JM; Bott MJ; Jones DR J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1212-1224.e3. PubMed ID: 29246549 [TBL] [Abstract][Full Text] [Related]
49. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Kim TJ; Goo JM; Lee KW; Park CM; Lee HJ Lung Cancer; 2009 May; 64(2):171-8. PubMed ID: 18799230 [TBL] [Abstract][Full Text] [Related]
50. The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. Cox ML; Yang CJ; Speicher PJ; Anderson KL; Fitch ZW; Gu L; Davis RP; Wang X; D'Amico TA; Hartwig MG; Harpole DH; Berry MF J Thorac Oncol; 2017 Apr; 12(4):689-696. PubMed ID: 28082103 [TBL] [Abstract][Full Text] [Related]
51. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M Chest; 2014 Jan; 145(1):66-71. PubMed ID: 24551879 [TBL] [Abstract][Full Text] [Related]
52. Diagnosis and treatment of high-risk bilateral lung ground-glass opacity nodules. Cheng M; Ding R; Wang S Asian J Surg; 2024 Jul; 47(7):2969-2974. PubMed ID: 38246790 [TBL] [Abstract][Full Text] [Related]
53. Intraoperative electromagnetic navigational bronchoscopic localization of small, deep, or subsolid pulmonary nodules. Abbas A; Kadakia S; Ambur V; Muro K; Kaiser L J Thorac Cardiovasc Surg; 2017 Jun; 153(6):1581-1590. PubMed ID: 28314525 [TBL] [Abstract][Full Text] [Related]
54. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278 [TBL] [Abstract][Full Text] [Related]
56. Long-term results after surgical treatment of the dominant lung adenocarcinoma associated with ground-glass opacities. Bongiolatti S; Corzani R; Borgianni S; Meniconi F; Cipollini F; Gonfiotti A; Viggiano D; Paladini P; Voltolini L J Thorac Dis; 2018 Aug; 10(8):4838-4848. PubMed ID: 30233857 [TBL] [Abstract][Full Text] [Related]
57. Nomogram for Predicting the Risk of Invasive Pulmonary Adenocarcinoma for Pure Ground-Glass Nodules. Wang L; Shen W; Xi Y; Liu S; Zheng D; Jin C Ann Thorac Surg; 2018 Apr; 105(4):1058-1064. PubMed ID: 29452996 [TBL] [Abstract][Full Text] [Related]
58. [Clinical Characteristics and Prognosis of Sub-centimeter Lung Adenocarcinoma]. Mi J; Wang S; Li X; Jiang G Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):500-506. PubMed ID: 31451140 [TBL] [Abstract][Full Text] [Related]
59. Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. Zhang Y; Deng C; Ma X; Gao Z; Wang S; Zheng Q; Xia G; Wen Z; Han H; Fu F; Liu Q; Hu H; Li Y; Wong KK; Chen H J Cancer Res Clin Oncol; 2020 Sep; 146(9):2411-2417. PubMed ID: 32356178 [TBL] [Abstract][Full Text] [Related]
60. Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis. Sun W; Feng L; Yang X; Li L; Liu Y; Lv N; Lin D Hum Pathol; 2018 Nov; 81():261-271. PubMed ID: 30420048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]